XBiotech Inc. (NASDAQ:XBIT)’s share price traded up 4.7% on Wednesday . The company traded as high as $14.15 and last traded at $14.14, with a volume of 59,305 shares. The stock had previously closed at $13.51.

A number of equities analysts have weighed in on the stock. Zacks Investment Research cut shares of XBiotech from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 20th. Noble Financial restated a “buy” rating and set a $30.00 price objective (up from $24.00) on shares of XBiotech in a research report on Tuesday, June 28th.

The stock’s market capitalization is $455.81 million. The stock has a 50 day moving average of $16.54 and a 200-day moving average of $12.35.

In related news, Director W Thorpe Mckenzie bought 20,000 shares of the firm’s stock in a transaction on Thursday, May 26th. The shares were bought at an average cost of $13.96 per share, for a total transaction of $279,200.00. Following the transaction, the director now owns 3,898,600 shares of the company’s stock, valued at $54,424,456. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.